Fujian Haixi Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Fujian Haixi Pharmaceuticals Co., Ltd. is a commercial-stage pharmaceutical company integrating R&D, production, and sales capabilities. The company operates primarily under the Market Authorization Holder (MAH) framework, enabling an asset-light business model. Haixi Pharma pursues a dual-line development strategy, balancing generic drugs and innovative drugs. Its generic portfolio emphasizes first-to-file, difficult-to-imitate, and high-quality products, leveraging national pharmaceutical policies. As of late 2025, the company had 15 approved generic drugs commercialized, primarily targeting digestive system diseases and cardiovascular system diseases, with a broader therapeutic scope including oncology, ophthalmology, endocrine, nervous systems, and inflammation. The innovative drug pipeline focuses on developing small-molecule drugs with significant unmet medical needs and global market potential, exemplified by its lead program, C019199.